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ABSTRACT 
Immune checkpoint regulators such as PD-L1 have become exciting new therapeutic 
targets leading to long lasting remissions in patients with advanced malignancies. 
However, in view of the remarkable costs and the toxicity profiles of these therapies, 
predictive biomarkers able to discriminate responders from non-responders are 
urgently needed. In the present paper, we provide evidence that PD-L1 is frequently 
expressed on metastatic cells circulating in the blood of hormone receptor-positive, 
HER2-negative breast cancer patients. We performed western blot, flow cytometry 
and immunocytochemical analyses to demonstrate the specificity of the PDL1 
antibody used in our study and established immunoscores for PDL1 expression on 
single tumor cells. We then selected sixteen patients with circulating tumor cells 
(CTCs) using the CellSearch® system and found PD-L1(+) CTCs in 11 patients 
(68.8%). The fraction of PD-L1(+) CTCs varied from 0.2 to 100% in individual patients. 
This is the first report demonstrating the expression of PD-L1 on CTCs. The 
established CTC/PD-L1 assay can be used for liquid biopsy in future clinical trials for 
stratification and monitoring of cancer patients undergoing immune checkpoint 
blockade. 
Key words: Circulating tumor cells, PD-L1 expression, Breast Cancer
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1.  Introduction 
The prognosis of cancer patients, even with localized primary tumors, is mainly 
determined by the circulation of tumor cells in the peripheral blood from the primary 
site to distant organs such as bone marrow, liver, lungs, or brain, and the subsequent 
outgrowth of a largely unknown subset of these cells into metastases in their new 
microenvironment (Eccles and Welch, 2007). The colonization of distant organs by 
disseminated tumor cells, resulting in the appearance of clinically detectable 
metastases, can take many years in breast cancer (Braun et al., 2005) and the 
mechanisms behind this "cancer dormancy" are largely unknown (Chambers et al., 
2002; Goss and Chambers, 2010; Uhr and Pantel, 2011). This stringent selection 
process together with a potential independent genomic progression of disseminated 
tumor cells may explain why overt metastases can harbor unique genomic alterations 
differing from the bulk of the original primary tumor cells (Flatmark et al., 2002; Kang 
and Pantel, 2013; Riethdorf et al., 2010). Thus, the direct analysis of metastatic cells 
could reveal important information for systemic cancer therapy targeting metastatic 
disease (Alix-Panabieres et al., 2012; Pantel et al., 2008). However, biopsy of overt 
metastases is an invasive procedure limited to certain locations and not easily 
acceptable in the clinic. Moreover, a recent work has shown that different metastatic 
sites harbour different genomic aberrations (Gerlinger et al., 2012) and biopsy of one 
or two accessible metastases may not be representative of the whole metastatic 
disease biology.  
An alternative approach is the analysis of blood samples for circulating tumor 
cells (CTCs) detection and characterization as a liquid biopsy of the cancer (Alix-
Panabieres and Pantel, 2014). It can be performed frequently and might allow real-
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time monitoring of cancer therapies in individual patients (Alix-Panabieres et al., 
2012). Recent reports indicated that CTCs give important complementary information 
on therapeutic targets and drug resistance mechanisms in carcinoma patients (Alix-
Panabieres and Pantel, 2014). CTCs isolated in the peripheral blood are a pool of 
cells derived from the primary tumor and different metastatic sites and may, 
therefore, provide a comprehensive real-time picture of the whole tumor burden in an 
individual patient (Pantel and Alix-Panabieres, 2013).   
 Characterization of tumor cells is of utmost importance. More specifically, PD-
L1 expressed in tumors has been recently highlighted to function as a key 
component of the cancer-immunity cycle by preventing the immune system from 
destroying cancer cells (Butt and Mills, 2014). PD-1 receptor (CD279) is expressed 
on the surface of activated T cells and its ligands, PD-L1 (B7-H1; CD274) and PD-L2 
(B7-DC; CD273), are expressed on the surface of antigen-presenting cells such as 
macrophages or dendritic cells. When PD-L1 binds to PD-1, a strong inhibitory signal 
is transmitted into the T cell, which induces a reduction of cytokine production and a 
suppression of T-cell proliferation (Brahmer et al., 2012; Chen et al., 2012; Topalian 
et al., 2012): the immune system is misled by the surrounding cancer cells 
expressing PD-L1 and does not destroy them. 
Efforts to restore latent anti-tumor immunity have focused on antibody-based 
interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 
(PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells (Shin and 
Ribas, 2015). Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor 
immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune 
function in the tumor microenvironment. Although ipilimumab can produce durable 
long-term responses in patients with advanced melanoma, it is associated with 
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significant immune-related toxicities (Shin and Ribas, 2015). By contrast, antibodies 
targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with 
considerably less toxicity (Shin and Ribas, 2015) and are being actively investigated 
for the treatment of multiple cancers including lung, breast, bladder and renal 
cancers (Philips and Atkins, 2015). Current efforts focus on registration trials of single 
agents and combinations in various diseases and settings, as well as on identifying 
predictive biomarkers of response. Ever since the earliest reports of the effects of 
PD-1 blockade, PD-L1 expression by tumor cells has been used as potential 
biomarker to predict a therapeutic response. We recently showed that the level of 
soluble PD-L1 present in the blood could predict patient’s outcome in aggressive B-
cell lymphomas (Rossille et al., 2014). However, the predictive value of PDL1 
expression measurements of primary carcinomas seems to be limited. Moreover, 
there is only a weak correlation in staining between the matched primary tumor and 
distant metastasis, suggesting that the primary tumor is not an adequate surrogate 
for determining PD-L1 expression in metastatic sites (Jilaveanu et al., 2014). Tissue 
heterogeneity in PD-L1 expression in both primary and metastatic sites for a given 
patient indicates that a single core biopsy might be not sufficient to determine tumor 
PD-L1 expression(Jilaveanu et al., 2014). 
CTCs are currently investigated as predictive biomarker for HER2-targeting 
therapies (Bidard et al., 2013) and the same strategy could be used for immune 
checkpoint blockade therapies such as antibodies to PD-L1. Jilaveanu et al. reported 
that distant sites have greater PD-L1 expression than the primary tumor (Jilaveanu et 
al., 2014). However, there is, to date, no report on the expression of PD-L1 on CTCs 
in breast cancer or other tumor entities. To investigate whether CTCs express PD-L1, 
we applied the CellSearch® system to blood samples from patients with metastatic 
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breast cancer before any treatment. Interestingly, we detected a subset of CTCs 
expressing PD-L1 in the blood of patients with metastatic breast cancer using a non-
invasive liquid biopsy. This specific subset represents metastatic cells with a high 
potential to escape T cell-mediated lysis and these cells are therefore the actual 
targets of anti-PDL1 antibody therapy. 
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2.  Materials and methods 
2.1.  Patient samples and blood collection 
After informed consent was given, peripheral blood from patients with hormone 
receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer was 
collected before the start of treatment (CPP number 2011-AOI163-38). Patients were 
recruited at the University Medical Centre of Montpellier (Department of Medical 
Oncology) and at the Montpellier Cancer Institute (ICM). Blood was drawn from the 
arm vein of each cancer patient in specific CellSave® tubes (Janssen, 10mL) for 
CTC detection. Tubes were then conserved at room temperature and sent to the 
Laboratory “Detection of Rare Human Circulating Cells – LCCRH” at the University 
Medical Center of Montpellier where blood samples were processed immediately on 
the CellSearch® system. The BRISQ criteria have been listed in the Table 1 (Moore 
et al., 2011). This study belongs to the BMS_PD-L1_onco clinical trial 
(NCT10660776), which assesses PD-L1 as a biomarker in oncology and hematology. 
2.2.  Cell culture 
Mammary cancer cell lines SKBR3 (ATCC® HTB-30™), MCF7 (ATCC® HTB-22™), 
MDA-MB-231 (ATCC® CRMHTB-26™) were purchased from the American Type 
Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(Eurobio, FR), 2µg/ml Gentamicin and 20UI/ml penicillin. Diffuse Large B-Cell 
Lymphoma (DLBCL) cell line SU-DHL-4 (ATCC® CRL-2957) cultured in RPMI 1640 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(Eurobio, FR), 2µg/ml Gentamicin and 20UI/ml penicillin. Cells were cultured in 25 
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cm2 flasks at 37°C in a humidified atmosphere conta ining 5% CO2. 
2.3.  CTC enumeration  
Seven and half milliliters of blood collected in the CellSave tube were used for CTC 
detection using the FDA-cleared CellSearch® system (Janssen, Beerse, Belgium).  
Blood samples were processed on the CellTracks Autoprep within 72h. The 
CellSearch® CXC Kit (Janssen) was used for these specific experiments. It includes 
a cytokeratin-fluorescein/CD45-allophycocyanin (APC) reagent, leaving the 
phycoerythrin (PE) channel of the Celltracks Analyzer II® open to incorporate a user-
defined PE-conjugate for further characterization of the CTCs. In our project, we 
improved the CTC detection by using the 4th channel of the CellSearch® for PD-L1 
expression: we used the anti-human B7-H1/PD-L1 PE-conjugated monoclonal 
antibody (MAb, Cat N° FAB1561P, R&D Systems, Minnea polis, USA) at a final 
concentration of 20 µg/mL. The corresponding isotypic control (Mouse IgG1 PE, Cat 
N° IC002P, R&D Systems, Minneapolis, USA) was used at the same final 
concentration (20 µg/mL). 
Briefly, fixed CTCs were first positively enriched via the epithelial cell adhesion 
molecule (EpCAM) expression and defined as EpCAM isolated intact cells stained 
positive for cytokeratins (CK8, 18, 19), positive or negative for B7H1 (PD-L1) and 
negative for CD45 (the exclusion marker specific of normal hematopoietic cells): 
CTCs were identified as EpCAM(+)DAPI(+)CK(+)CD45(-).  
As control group, we analysed in parallel blood samples from 15 healthy controls 
provided by the regional centre of blood transfusion (Etablissement Français du Sang 
of Montpellier, France).  
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2.4.  Flow cytometry experiments 
A fixation/permeabilization kit (Beckman Coulter, Brea, USA) was used to prepare 
the cells before the addition of the anti-human B7H1 Ab or Mouse IgG1 PE at a final 
concentration of 20 µg/mL on 0.2 million SKBR3 cells and 0.2 SU-DHL-4. Briefly, 
cells and both Abs were incubated for 60 min at room temperature in the dark. Cells 
were then washed with PBS supplemented with 2% fetal bovine serum, centrifuged 
(600g – 5 min) and the cell pellet was recovered with 400µL PBS. Labelled cancer 
cells were detected by using the Cyan cytometer (Beckman Coulter) and the data 
analysis was performed using the Kaluza software (Beckman Coulter).  
Other anti-human B7H1 Abs have been tested: (1) clone 3.1 anti-CD274-PE Ab (ref 
IM99509, Beckman Coulter), (2) anti-CD274-FITC (ref 558065, Becton Dickinson), 
and (3) B7-H1-A488 (ref FAB1561G, R&D Systems). As shown by the Figure 1, a 
direct ELISA on different proteins showed the specificity of the anti-human B7H1 
MAb, (Cat N° FAB1561P, R&D Systems; data given by R &D systems).    
2.5.  Immunocytochemical analyses 
SKBR3 cancer cells were labelled as described above using the concentration of the 
anti-human B7-H1 MAb required for the CellSearch® system (20 µg/mL) and 
centrifuged gently in a Cytospin 4 Cytocentrifuge (Thermo Scientific) on standard 
glass slides. A drop of the ProLong Gold antifade reagent with DAPI (Invitrogen, 
Ref-P36931) was added on the preparation to stain nuclei in blue and slides were 
mounted. Stained cancer cells were finally observed under a fluorescent microscope 
(Axio Imager.M1, Zeiss) and automatically analyzed with the software AxioVision 
Release 4.6.3. 
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2.6. Western Blot analysis 
The primary anti-PD-L1 B7-H1/PD-L1 MAb (IgG1 Clone #130021, Cat N° MAB1561, 
R&D Systems) was analyzed versus the Mouse IgG1 Isotype Control (mouse 
monoclonal, Clone #11711, Cat N° MAB002, R&D System s). As a loading control, 
anti-alpha-Tubulin (11H10) antibody, from Cell Signaling Technology (Danvers, USA) 
was used. Protein samples from the cell lines MDA-MB-468, MDA-MB-231, BT-20, 
PC-3, LNCAP, Du145, SCC25, Cal27, MDA-MB-231-SA, BC-M1, PC-E1 and SU-
DHL-4 were analyzed. Cells were harvested in 9.8 M urea, 15 mM EDTA, 30 mM 
Tris, followed by a cell disruption step by ultrasonic treatment. Insoluble compounds 
were removed by centrifugation and the supernatant was collected. The protein 
concentration was determined using the Pierce BCA Protein Assay Kit (Pierce, 
Rockford, USA) using BSA as the standard. Proteins were separated by SDS-PAGE 
using either the Novex XCell Sure-Lock mini system (Invitrogen, Groningen, 
Netherlands) or the Protean II xi cell (Bio-Rad, Hercules, USA). A Laemmli buffer 
system and 10% polyacrylamide separation gels were used. The molecular size 
standard was the peqGOLD protein-marker V (Peqlab, Erlangen, Germany). The 
proteins were transferred to Immobilon-PSQ membranes (Millipore GmbH, 
Schwalbach, Germany) using the mini VE vertical electrophoresis system equipped 
with tank blot transfer units (GE Healthcare, Uppsala, Sweden). The primary 
antibodies were applied to the membranes at 4 °C wi th gentle agitation over night. 
Protein bands were detected using the SignalFire ECL Reagent (Cell Signaling 
Technology) and X-ray films (GE Healthcare). X-ray films were digitized using the 
GS-700 imaging densitometer (Bio-Rad). 
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3.  Results 
3.1.  Establishment of the B7-H1/PD-L1 CTC analysis.  
For the establishment of a novel assay detecting CTCs expressing PD-L1, the 
sensitivity, specificity and the dynamic range of the PD-L1 R&D antibody was 
determined by Western Blot in an array of experiments and cell lines. The PD-L1 
R&D antibody was found to detect very low levels of PD-L1, provided only one strong 
signal at approx. 55 kDa and exhibited a linear increase of the signal intensity 
proportional to the applied protein amount. For the isotype control very weak or no 
signal at all was detected in the analyzed cell lines (Figure 2A). MDA-MB-231 served 
as a useful positive control for the establishment of the Western Blot. However, the 
extraordinary high signal intensity of the PD-L1 R&D antibody frequently resulted in 
oversaturation of the signals in the Western Blots. To circumvent oversaturation of 
the signals in subsequent immunofluorescent assays, we therefore focused on the 
cell line SKBR3, because these cells show a range of levels of PD-L1 expression, 
which enabled us to develop immunoscores for various degrees of PDL1 on single 
tumor cells.  
Next, we analyzed the different breast cancer cell lines SKBR3, MCF-7 and MDA-
MB-231 by flow cytometry. All these cell lines were positive for PD-L1 (data not 
shown). The presence of PD-L1 on SKBR3 cells was confirmed by flow cytometry 
(Figure 2B) and immunofluorescent staining of cytospins (Figure 2C). The specificity 
of the staining was demonstrated by the fact that no signals were detected for the cell 
line SU-DHL-4 (established negative control) and for the isotype control on SKBR3 
cells. Next, SKBR3 (PD-L1(+)) and SU-DHL-4 (PD-L1(-)) were analyzed for PD-L1 
using the CellSearch® system with PD-L1 implemented in the 4th channel (Fig. 2D).  
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We selected the anti-human B7-H1/PD-L1 PE-conjugated monoclonal antibody 
(MAb) from R&D. Other anti-human B7H1 Abs have been also tested at different 
concentrations with the CellSearch® system: (1) clone 3.1 anti-CD274-PE Ab (ref 
IM99509, Beckman Coulter), (2) anti-CD274-FITC (ref 558065, Becton Dickinson), 
and (3) B7-H1-A488 (ref FAB1561G, R&D Systems). However, a concentration of 
only 20 µg/mL of the PE-conjugated monoclonal antibody (MAb) from R&D was 
needed to get an optimal staining, whereas a concentration of 40 µg/mL was 
necessary for all the other antibodies (data not shown). 
When we performed additional experiments with the CellSearch® system dedicated 
for CTC detection on pure SKBR3, we could observe single PD-L1(+) SKBR3 tumor 
cells (Figure 3A) as well as clusters (Figure 3B) of PD-L1(+) SKBR3 tumor cells. 
Moreover, we defined a “PD-L1 immunoscore” with three different scores for the 
intensity of PD-L1 expression by single SKBR3 tumor cells and SKBR3 tumor cell 
clusters: score 0 (no PD-L1 expression), score 1 (low PD-L1 expression) and score 2
(high PD-L1 expression) (Figure 3). 
3.2.  Spiking experiments of SKBR3 in control blood
We performed spiking experiments by adding 200 SKBR3 cells in 7.5 mL of blood 
from healthy donors and detected the breast cancer cells using the CellSearch®
system with the CellSearch® CXC Kit. These results demonstrated the feasibility to 
detect PD-L1(+) tumor cells in blood samples with this technology dedicated for CTC 
detection. SKBR3 cells could be detected with a recovery rate of 79.5%, which is 
consistent with the results obtained the standard CTC kit (Riethdorf et al., 2007). 
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3.3.  PD-L1(+) CTC from metastatic breast cancer patients  
Peripheral blood samples from HR(+), HER2(-) metastatic breast cancer patients (one 
male, fifteen females) were analyzed by the CellSearch® system implemented with 
the PD-L1 detection by using the optimized conditions described above. For our 
study, we selected sixteen patients with a CTC count ≥1 using the CellSearch®
system (mean, 254.5; median, 18.5; Range, 1-3146) and 13 of 16 (81.3%) patients 
with a CTC count ≥5 (mean, 312.5; median, 27; Range, 7-3146), the prognostic cut-
off for patients with metastatic breast cancer (Cristofanilli et al., 2004) (Table 2). 
Eleven patients out of 16 showed a subpopulation of CTCs expressing PD-L1 
(68.8%) scored 1 or 2 (Table 2; Figure 4A). The fraction of PD-L1(+) CTCs varied 
from 0.2 to 100% (Table 2). However, this information may also depend on the 
number of detected CTCs. If only patients with more or equal than 10 CTCs are 
considered, the fraction of PD-L1(+) CTCs varied from 0.2 to 50% (Table 2). The 
intensity of PD-L1 staining varied between patients and within the same blood 
sample. Analyzing samples with multiple CTCs showed that six patients had CTCs 
with mixed PDL1 phenotypes (immunoscores 1 and 2), whereas homogeneous PDL1 
immunoscores were only found in one patient (Table 2).  
As shown in the Figure 4B, we could also easily observe and distinguish PD-L1(+) 
leucocytes next to CTCs positive or not for the expression of PD-L1. Leucocytes 
express CD45, while CTCs are defined in the CellSearch® system as CD45(-).  
As negative controls, we tested blood samples from 15 healthy controls and 
confirmed that none of the samples were positive for CTCs (Data not shown). 
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4.  Discussion 
In the present paper, we provide evidence that PD-L1 is frequently expressed on 
metastatic cells circulating in the blood of HR(+), HER2(-) breast cancer patients. To 
our best knowledge, this is the first report demonstrating the expression of PD-L1 on 
CTCs in any cancer entity. Detection of CTCs expressing PD-L1 means that the 
patients harbor metastatic tumor cells that may have the capacity to block the 
immune system. These cells are potential targets for anti-PDL1 therapies. This 
information is fundamentally different from the detection of shed PD-L1 in the blood 
serum or plasma, which provides no information on the cellular source of PD-L1.  
The sensitivity, specificity and the dynamic range of the PD-L1 MAb that we chose in 
our study was determined by Western Blot, flow cytometry and immunocytochemical 
analyses. We tested different mammary cancer cell lines (i.e., MDA-MB-231, MCF-7 
& SKBR3) and as PD-L1 was expressed at variable degrees on SKBR3, we selected 
it as our positive control for the establishment of our novel assay detecting CTCs 
expressing PD-L1. We could thus established immunoscores for PD-L1 expression 
on single SKBR3 cells with this anti-human B7-H1 MAb and then validated these 
scores on blood samples from patients with a HR(+), HER2(-) metastatic breast 
cancer. This strategy has been adapted from previous reports using the CellSearch®
system for immunophenotyping of CTCs (Ignatiadis et al., 2011; Riethdorf et al., 
2010).  
Despite the fact that we only analyzed a limited number of patients, our results 
clearly showed that PD-L1 is frequently expressed on CTCs. However, the 
percentage of PD-L1(+) CTCs in individual patients varied considerably. In particular, 
patients with a high percentage of PD-L1(+) CTCs should be potential candidate for 
anti-PD-L1 therapy. The established CTC/PD-L1 assay can be used in further trials 
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for stratification and monitoring of cancer patients. It should be noted that only 
EpCAM(+) CTCs were analysed, so the real number of PDL1(+) CTCs might be even 
higher. However, we decided to implement the PD-L1 staining into the EpCAM-
dependent CellSearch® system because it is still the only automated technical 
platform cleared by the FDA-USA with a remarkable reproducibility. 
The present finding has obvious clinical implications. Immune checkpoint regulators 
such as PD-L1 have become exciting new therapeutic targets leading to long lasting 
remissions in patients with advanced malignancies (Shin and Ribas, 2015). However, 
in view of the remarkable costs and the toxicity profiles (in particular during 
combination therapy) of these therapies, predictive biomarkers that are able to 
discriminate responders from non-responders are urgently needed. The development 
of metastasis in breast cancer (and other solid tumors) can take many years and the 
metastatic cells may differ from the original cells in the operated primary lesion (Goss 
and Chambers, 2010). Thus, re-staging of metastatic lesion is required to get real-
time information on the molecular characteristics of the actual metastatic cells that 
are the targets of antibody therapy (not the primary tumor). However, biopsies of 
metastatic lesions are an invasive procedure with considerable side effects 
depending on the site of metastasis and, moreover, different metastatic sites can 
have different molecular characteristics(Gerlinger et al., 2012).  
As an alternative, we previously introduced a new diagnostic concept called “liquid 
biopsy” (Alix-Panabieres and Pantel, 2013; Pantel and Alix-Panabieres, 2010). 
Standardized automated analysis of CTCs for PD-L1 is feasible, as demonstrated in 
the present investigation. This protocol can be easily expanded to other immune 
checkpoint molecules and other carcinoma entities. Implementing these liquid biopsy 
analyses into future clinical trials of checkpoint blockade might not only be useful for 
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therapy stratification but CTC analyses performed in real-time before and during the 
course of the therapy will provide, in addition, important information on the 
development of resistance.  
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Figure Legends 
Figure 1 – Human B7H1 Detection in direct ELISA with monoclonal anti-human 
B7-H1. Antibody: Human B7-H1 monoclonal Ab (R&D systems). Different proteins 
have been analyzed: recombinant human B7-H1, recombinant human B7-1, 
recombinant human B7-2, recombinant B7-H2, recombinant human B7-H3, 
recombinant human B7-H3b, recombinant human B7-H4, recombinant B7-H6, 
recombinant B7-H7, recombinant human PD-L2 and recombinant mouse B7-H1. The 
plate was coated with recombinant protein at mass/well cited in the graph. The 
different concentrations used were: primary Ab (0.5 µg/mL), secondary Ab (goat anti-
mouse IgG polyclonal antibody-biotinylated at 1:10,000), enzyme (streptavidin-AP at 
1/1000); the substrate was the p-nitrophenyl phosphate. Abbreviations: rh: 
recombinant human; rm: recombinant mouse.   
Figure 2 – Specificity and sensitivity of the anti-human B7H1 MAb (R&D 
system). A, Determination of the anti-human B7H1 MAb recognition profile on 
test protein mixtures from the assigned cell lines and tumour entities by 
Western Blot. In parallel, the protein recognition pattern for the mouse isotype 
control was analyzed. For each lane 20 µg of protein was loaded. Both membranes 
were exposed to the same X-ray films. To investigate the band pattern for the two 
antibodies, a short X-ray film exposition time (10 sec) and an overexposed X-ray film 
(4 min) is shown. Alpha Tubulin served as a loading control. B, Flow cytometry 
analyses. SKBR3 and SU-DHL-4 cell lines were incubated with the anti-human B7-
H1 MAb-PE (in red) and the corresponding isotypic control (IgG1, in blue) – The flow 
cytometer used for all the analyses was the Cyan (Beckman Coulter); C, 
Immunocytochemical analyses. SKBR3 and SU-DHL-4 cells were centrifuged 
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gently in a Cytospin 4 Cytocentrifuge (Thermo Scientific) on standard glass slides 
after being stained with the anti-human B7-H1-PE MAb and the corresponding 
isotypic control. DAPI was added on the preparation to stain nuclei in blue. PDL1(+)
tumor cells are stained in red (Fluorescent microscope Axio Imager.M1 Zeiss, 
software AxioVision Release 4.6.3. - magnification X20). D, CellSearch® system 
analyses. SKBR3 and SU-DHL-4 were analyzed in the CellSearch® system using 
either the human anti-human B7-H1 MAb-PE or the corresponding isotypic control in 
the 4th channel (PE). All experiments were repeated 3 times and the figures 
show representative results. 
Figure 3 – Detection of PD-L1 expression on SKBR3 cells with the CellSearch®
system. A, Single SKBR3 cells with different levels of PD-L1 expression 
(B7H1PE in the 4th channel): score 0 (no PD-L1 expression), 1 (weak PD-L1 
expression) and 2 (strong PD-L1 expression); B, SKBR3 clusters with different 
PD-L1 immunoscores. 
Figure 4 – CTCs expressing various degrees of PD-L1 detected in blood of 
HR(+) HER2(-) metastatic breast cancer patients with the CellSearch® system. 
Representative pictures of CTCs classified by scores 0, 1 and 2 for PD-L1 
expression. 
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